信立泰：SAL0139药品临床试验申请获受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0139, which is intended for the treatment of hyperlipidemia [1] Company Summary - The drug SAL0139 is developed by the company and possesses independent intellectual property rights [1] - The application submitted by the company is specifically for conducting clinical trials of SAL0139 for hyperlipidemia treatment [1]